105 related articles for article (PubMed ID: 24656887)
1. Concurrent estrogen action was essential for maximal progestin effect in oral contraceptives.
Bono Y; Kyo S; Kiyono T; Mizumoto Y; Nakamura M; Maida Y; Takakura M; Fujiwara H
Fertil Steril; 2014 May; 101(5):1337-43. PubMed ID: 24656887
[TBL] [Abstract][Full Text] [Related]
2. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer.
Faber MT; Jensen A; Frederiksen K; Glud E; Høgdall E; Høgdall C; Blaakaer J; Kjaer SK
Cancer Causes Control; 2013 Dec; 24(12):2197-206. PubMed ID: 24077761
[TBL] [Abstract][Full Text] [Related]
4. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
5. [Metabolic impact of current estrogen-progestins and cardiovascular consequences].
Gaspard U; Lambotte R
Bull Mem Acad R Med Belg; 1991; 146(8-10):334-42; discussion 342-5. PubMed ID: 1815814
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptives: mechanism of action, dosing, safety, and efficacy.
Sondheimer SJ
Cutis; 2008 Jan; 81(1 Suppl):19-22. PubMed ID: 18338654
[TBL] [Abstract][Full Text] [Related]
7. [Influence of estrogen and progestin on nm23-H1 expression in epithelial ovarian cancer cell lines via activation of phosphorylation signaling].
Hua KQ; Yao LQ; Cao Q; Huang Y; Zhao YQ; Feng YJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):756-61. PubMed ID: 17327034
[TBL] [Abstract][Full Text] [Related]
8. [How to choose an oral contraceptive in 1984].
Rozenbaum H
Contracept Fertil Sex (Paris); 1984 Nov; 12(11):1201-6. PubMed ID: 12266609
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
10. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk.
Lurie G; Thompson P; McDuffie KE; Carney ME; Terada KY; Goodman MT
Obstet Gynecol; 2007 Mar; 109(3):597-607. PubMed ID: 17329510
[TBL] [Abstract][Full Text] [Related]
11. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
[TBL] [Abstract][Full Text] [Related]
12. Oral contraception with estrogen and progestin combinations.
Board JA
Curr Ther Res Clin Exp; 1971 Jan; 13(1):1-5. PubMed ID: 4992561
[No Abstract] [Full Text] [Related]
13. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
[TBL] [Abstract][Full Text] [Related]
14. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions.
Ness RB; Grisso JA; Klapper J; Schlesselman JJ; Silberzweig S; Vergona R; Morgan M; Wheeler JE
Am J Epidemiol; 2000 Aug; 152(3):233-41. PubMed ID: 10933270
[TBL] [Abstract][Full Text] [Related]
15. The formulation of oral contraceptives: does the amount of estrogen make any clinical difference?
Speroff L
Johns Hopkins Med J; 1982 May; 150(5):170-6. PubMed ID: 7043035
[TBL] [Abstract][Full Text] [Related]
16. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.
Schildkraut JM; Calingaert B; Marchbanks PA; Moorman PG; Rodriguez GC
J Natl Cancer Inst; 2002 Jan; 94(1):32-8. PubMed ID: 11773280
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptives decrease the prevalence of ovarian cancer in the hen.
Treviño LS; Buckles EL; Johnson PA
Cancer Prev Res (Phila); 2012 Feb; 5(2):343-9. PubMed ID: 22135044
[TBL] [Abstract][Full Text] [Related]
18. [Endocrinological contribution for invasion and metastasis in gynecological cancers].
Fujimoto J
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):633-43. PubMed ID: 8808831
[TBL] [Abstract][Full Text] [Related]
19. Formulation and noncontraceptive uses of the new, low-dose oral contraceptive.
Batzer FR
J Reprod Med; 1984 Jul; 29(7 Suppl):503-12. PubMed ID: 6237195
[TBL] [Abstract][Full Text] [Related]
20. [Oral contraception: disadvantages of estrogen reduction].
Denis C
Contracept Fertil Sex (Paris); 1993 Jun; 21(6):481-8. PubMed ID: 12318238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
